ARV-471, a PROTAC® estrogen receptor (ER) degrader, in people with ER-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer

This summary contains information from the scientific oral presentation:

ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study

CLICK HERE TO VIEW THE SCIENTIFIC PRESENTATION

What is ER+/HER2- advanced breast cancer?

ER+/HER2- breast cancer is one type of breast cancer

- Certain types of breast cancer grow in response to **estrogen**, a hormone (or **chemical messenger**) in your body. This is called **estrogen receptor-positive** (**ER+**) breast cancer
- Some types of breast cancer have a lot of a protein called **human epidermal growth factor receptor 2** (**HER2**) and are called **HER2-positive** (**HER2+**). Other breast cancer types have low levels or no HER2 and are called **HER2-negative**

Advanced breast cancer is cancer that has spread from the breast to nearby tissue (**locally advanced cancer**) or from the breast to more distant parts of the body (**metastatic cancer**)



What are the different types of treatments for ER+/HER2- advanced breast cancer?

Some treatments, called **endocrine therapies**, work by either blocking the body's ability to produce hormones, such as estrogen, or blocking the activity of these hormones in cancer cells. This may slow or stop cancer growth

- **Aromatase inhibitors**, such as letrozole or anastrozole, are endocrine therapies that reduce the production of estrogen
- **Fulvestrant** is an endocrine therapy that binds estrogen receptors leading to degradation, which reduces estrogen's effects on tumors

Chemotherapy is a treatment that damages cancer cells. Sometimes people get it prior to surgery to shrink the size of their tumor, or after surgery to kill lingering cancer cells

CDK4/6 inhibitors are another type of treatment and work by blocking certain proteins that cause cancer cells to grow

What is ARV-471?

ARV-471 is a drug that is being researched for treating ER+/HER2- advanced breast cancer. It works by **causing estrogen receptors to be eliminated** by a natural protein disposal system in the body

- Elimination of estrogen receptors blocks the activity of estrogen and could potentially stop ER+ breast cancer tumors from growing or cause the tumors to shrink

In the first part of a **clinical study that tested different doses of ARV-471** in people with ER+/HER2- advanced breast cancer:

- **40%** of the people who could be evaluated had **tumors that remained stable** (neither grew nor shrank) or **shrank following ARV-471 treatment**
- The **side effects of ARV-471** were **mostly mild or moderate**

In this second part of the clinical study, researchers **tested 2 doses of ARV-471** in 71 people with breast cancer

The aims of this study were to find out

- **If ARV-471 can cause tumors to stop growing or shrink** in people with ER+/HER2- advanced breast cancer
- **If ARV-471 is a safe treatment** for people with ER+/HER2- advanced breast cancer
- The **best dose of ARV-471** for future studies in people with ER+/HER2- advanced breast cancer

This summary describes

- The **side effects** that people with ER+/HER2- advanced breast cancer experienced while taking ARV-471 and **how well ARV-471 caused tumors to stop growing or shrink**

Study Population

WHO TOOK PART IN THIS STUDY?

71 people with ER+/HER2- locally advanced or metastatic breast cancer participated in this study

TOOK THE LOWER DOSE



TOOK THE HIGHER DOSE

Before the study

received a CDK4/6 inhibitor

received an aromatase inhibitor

received fulvestrant

received chemotherapy

During the study

Participants took ARV-471 as pills by mouth each day

Results

WHAT WERE THE RESULTS OF THE STUDY?

People taking ARV-471 experienced **mostly mild or moderate side effects**. The most common side effects were:



[a]AST is aspartate aminotransferase, a substance produced by the liver

Side effects were **generally similar with the lower and higher doses** of ARV-471

Tumors shrank or stopped growing in 38% of people taking ARV-471

of those taking the **lower dose**

of those taking the **higher dose**

Half of the people who took the lower dose of ARV-471 lived without their cancer getting worse for

People taking the higher dose need to have longer follow-up in the study to understand how long they lived without their cancer getting worse

In 9 people who could be evaluated and were taking the lower dose of ARV-471 in the first or second part of the clinical study, the **amount of estrogen receptor** in their tumors **decreased by an average of 71%**

TAKE-HOME MESSAGES

- Treatment with ARV-471 shows **clinical benefits for people with ER+/HER2- advanced breast cancer**
- Most of the side effects with ARV-471 were **mild or moderate**
- A **larger study will compare ARV-471 vs fulvestrant** in people with ER+/HER2- advanced breast cancer
  - The **lower dose of ARV-471 was selected** to use in the larger study based on the results from this study

Who sponsored this study?

This study was sponsored by **Arvinas Estrogen Receptor, Inc.**

Arvinas Operations, Inc.
5 Science Park
395 Winchester Ave.
New Haven, CT 06511
Phone (United States): +1 203-535-1456

Arvinas thanks the **people who volunteered to participate in this study** and **their caregivers**, as well as the **investigators, researchers, and coordinators** who are contributing to this study

Writing and editorial support for this summary was provided by Britt Anderson, PhD, and Paula Stuckart of Apollo Medical Communications and funded by Arvinas Operations, Inc.

Where can I find more information?

For more information on **this study**

VIEW CLINICAL TRIAL RECORD

For more information on **clinical studies in general**, please visit https://www.clinicaltrials.gov/ct2/about-studies/learn

https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/what-clinical-trials-are